Ratings for Privia Health Gr (NASDAQ:PRVA) were provided by 12 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 7 | 3 | 2 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 3 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 2 | 3 | 2 | 0 | 0 |
Analysts have set 12-month price targets for Privia Health Gr, revealing an average target of $26.42, a high estimate of $37.00, and a low estimate of $21.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 16.92%.
Decoding Analyst Ratings: A Detailed Look
The standing of Privia Health Gr among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Jailendra Singh | Truist Securities | Lowers | Buy | $24.00 | $28.00 |
| Richard Close | Canaccord Genuity | Lowers | Buy | $26.00 | $37.00 |
| Craig Jones | Stifel | Lowers | Buy | $24.00 | $28.00 |
| Daniel Grosslight | Citigroup | Announces | Buy | $25.00 | - |
| Richard Close | Canaccord Genuity | Lowers | Buy | $37.00 | $41.00 |
| Lisa Gill | JP Morgan | Lowers | Overweight | $30.00 | $38.00 |
| Andrew Mok | Barclays | Announces | Equal-Weight | $22.00 | - |
| Andrew Mok | UBS | Lowers | Buy | $29.00 | $31.00 |
| Gary Taylor | TD Cowen | Lowers | Outperform | $26.00 | $30.00 |
| Jailendra Singh | Truist Securities | Lowers | Buy | $28.00 | $32.00 |
| Elizabeth Anderson | Evercore ISI Group | Lowers | Outperform | $25.00 | $26.00 |
| Adam Ron | B of A Securities | Lowers | Neutral | $21.00 | $27.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Privia Health Gr. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Privia Health Gr compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Privia Health Gr's stock. This comparison reveals trends in analysts' expectations over time.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Privia Health Gr's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Privia Health Gr analyst ratings.
Delving into Privia Health Gr's Background
Privia Health Group Inc is a technology-driven, national physician-enablement company. It collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual care settings.
Unraveling the Financial Story of Privia Health Gr
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, Privia Health Gr showcased positive performance, achieving a revenue growth rate of 7.5% as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Privia Health Gr's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 0.72%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Privia Health Gr's ROE excels beyond industry benchmarks, reaching 0.52%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Privia Health Gr's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.29%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
The Basics of Analyst Ratings
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.